Innovative Medicines Initiative 2 (IMI2) published indicative topics for the future calls.

The following topics are under consideration for inclusion in Calls for proposals to be launched in late 2015 and early 2016:

• Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
• Validation of translational imaging methods in drug safety assessment (TRISTAN)
• Identification of drugable targets modulating misfolded proteins in major neurodegenerative diseases
• Pathological neuron-glia interactions in neuropathic pain
• Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention
• A comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer
• Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD)

Topics under the Big Data for Better Outcomes Programme:

• Coordination and support action (CSA) for the big data for better outcomes programme
• Increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients

Further information: http://www.imi.europa.eu/content/future-topics

Remark: All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.

Contact person at EPC